Login to Your Account


Neurocrine raises $142M to push VMAT2 inhibitor; phase III design ahead

By Randy Osborne
Staff Writer

Thursday, February 27, 2014
Pulling down about $142 million from a public offering of 8 million shares priced at $17.75 each, Neurocrine Biosciences Inc. is moving ahead with phase III plans for the vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia candidate NBI-98854.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription